@KingBuzzo@johndprent
Agree about de-risking. But, the urgency? Not so sure.
IMHO, the US phase 2/3 trial is not likely to start before 2024, which gives RAC plenty of time to get the IND right. A BP transaction might even happen before the phase 2/3 trial even starts.
On the other hand, to prepare the IND, RAC need to scope the trial protocol. They want the IND to go through, but they also need to ensure the trial is scoped perfectly. This takes time in itself.
Then, there is a lot of dependents that likely inform the trial scoping. Starting with interim results for the phase 2 EM AML being (currently pending patient recruitment & dosage). Followed by, the companion diagnostic as it would make sense to use it in the trial. Finally, new formulation (granted, the new formulation is expected to be for the solid tumour trial).
In summary, and as the BOD said before, "measure a hundred times, cut once".
Ann: Race investor briefing invitation, page-21
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.54 |
Change
-0.015(0.97%) |
Mkt cap ! $261.5M | |||
| Open | High | Low | Value | Volume |
| $1.55 | $1.55 | $1.50 | $111.4K | 73.35K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.56 | 1400 | 1 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |